Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242076 | 0.84 | CA1 (0.50) | CA1CA2KDM1AHDAC1KMT2A | |
| SCHEMBL12521156 | 0.82 | CA1 (0.46) | CA1CA2KDM1AKDM4ECCR3 | |
| SCHEMBL3241218 | 0.82 | CA1 (0.46) | CA1CA2KDM1AHDAC1KMT2A | |
| SCHEMBL3232261 | 0.80 | CA1 (0.53) | CA1CA2HDAC1KMT2AGAA | |
| SCHEMBL5177175 | 0.79 | CA1 (0.52) | CA1CA2HDAC1KMT2AGAA | |
| SCHEMBL3243773 | 0.79 | TAAR1 (0.54) | CA1CA2HDAC1KMT2AGAA | |
| SCHEMBL5178076 | 0.79 | TAAR1 (0.54) | CA1CA2KMT2AKDM4E | |
| SCHEMBL3571060 | 0.79 | HDAC1 (0.62) | CA1CA2HDAC1GAAMAPT | |
| SCHEMBL3237476 | 0.79 | CA1 (0.47) | CA1CA2KDM4ECCR3 | |
| SCHEMBL3241151 | 0.79 | CA1 (0.47) | CA1CA2HDAC1KDM4ECCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984322-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-09-26 | — | — | EP | disclosed |
| US-7745477-B2 | Heteroaryl and benzyl amide compounds | HOFFMAN-LA ROCHE INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | CYP1B1, CYP4B1, ABCG2 | CA1 4780/4885CA2 3882/4885KDM1A 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.